Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis.

Chitnis T, Arnold DL, Banwell B, Brück W, Ghezzi A, Giovannoni G, Greenberg B, Krupp L, Rostásy K, Tardieu M, Waubant E, Wolinsky JS, Bar-Or A, Stites T, Chen Y, Putzki N, Merschhemke M, Gärtner J; PARADIGMS Study Group.

N Engl J Med. 2018 Sep 13;379(11):1017-1027. doi: 10.1056/NEJMoa1800149.

2.

Relapse Rate and MRI Activity in Young Adult Patients With Multiple Sclerosis: A Post Hoc Analysis of Phase 3 Fingolimod Trials.

Gärtner J, Chitnis T, Ghezzi A, Pohl D, Brück W, Häring DA, Karlsson G, Putzki N.

Mult Scler J Exp Transl Clin. 2018 May 25;4(2):2055217318778610. doi: 10.1177/2055217318778610. eCollection 2018 Apr-Jun.

3.

Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study.

Miller DH, Lublin FD, Sormani MP, Kappos L, Yaldizli Ö, Freedman MS, Cree BAC, Weiner HL, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BMJ, MacManus DG, Yousry TA, Gandini Wheeler-Kingshott CAM, Li B, Putzki N, Merschhemke M, Häring DA, Wolinsky JS.

Ann Clin Transl Neurol. 2018 Jan 30;5(3):346-356. doi: 10.1002/acn3.534. eCollection 2018 Mar.

4.

A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo.

Vermersch P, Radue EW, Putzki N, Ritter S, Merschhemke M, Freedman MS.

Mult Scler J Exp Transl Clin. 2017 Sep 27;3(3):2055217317730096. doi: 10.1177/2055217317730096. eCollection 2017 Jul-Sep.

5.

Rebound Syndrome in Multiple Sclerosis After Fingolimod Cessation.

Merschhemke M, Tomic D, Putzki N.

JAMA Neurol. 2016 Nov 1;73(11):1375. doi: 10.1001/jamaneurol.2016.3199. No abstract available.

PMID:
27669336
6.

The association between retinal nerve fibre layer thickness and N-acetyl aspartate levels in multiple sclerosis brain normal-appearing white matter: a longitudinal study using magnetic resonance spectroscopy and optical coherence tomography.

Pardini M, Botzkowski D, Müller S, Vehoff J, Kuhle J, Ruberte E, Würfel J, Gass A, Valmaggia C, Tettenborn B, Putzki N, Yaldizli Ö.

Eur J Neurol. 2016 Dec;23(12):1769-1774. doi: 10.1111/ene.13116. Epub 2016 Sep 3.

PMID:
27591406
7.

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.

Lublin F, Miller DH, Freedman MS, Cree BAC, Wolinsky JS, Weiner H, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BMJ, Merschhemke M, Li B, Putzki N, Liu FC, Häring DA, Kappos L; INFORMS study investigators.

Lancet. 2016 Mar 12;387(10023):1075-1084. doi: 10.1016/S0140-6736(15)01314-8. Epub 2016 Jan 28. Erratum in: Lancet. 2017 Jan 21;389(10066):254.

PMID:
26827074
8.

Longitudinal changes in self-reported walking ability in multiple sclerosis.

Motl RW, Putzki N, Pilutti LA, Cadavid D.

PLoS One. 2015 May 1;10(5):e0125002. doi: 10.1371/journal.pone.0125002. eCollection 2015.

9.

Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management.

Arvin AM, Wolinsky JS, Kappos L, Morris MI, Reder AT, Tornatore C, Gershon A, Gershon M, Levin MJ, Bezuidenhoudt M, Putzki N.

JAMA Neurol. 2015 Jan;72(1):31-9. doi: 10.1001/jamaneurol.2014.3065.

10.

Timed 25-foot walk: direct evidence that improving 20% or greater is clinically meaningful in MS.

Hobart J, Blight AR, Goodman A, Lynn F, Putzki N.

Neurology. 2013 Apr 16;80(16):1509-17. doi: 10.1212/WNL.0b013e31828cf7f3. Epub 2013 Mar 27. Review.

PMID:
23535489
11.

Historical overview of the rationale for the pharmacological use of prolonged-release fampridine in multiple sclerosis.

Fernandez O, Berger T, Hartung HP, Putzki N.

Expert Rev Clin Pharmacol. 2012 Nov;5(6):649-65. doi: 10.1586/ecp.12.59. Epub 2012 Nov 13.

PMID:
23146002
13.

Fatigue and progression of corpus callosum atrophy in multiple sclerosis.

Yaldizli Ö, Glassl S, Sturm D, Papadopoulou A, Gass A, Tettenborn B, Putzki N.

J Neurol. 2011 Dec;258(12):2199-205. doi: 10.1007/s00415-011-6091-0. Epub 2011 May 19.

PMID:
21594686
14.

Vitamin D levels in Swiss multiple sclerosis patients.

Yildiz M, Tettenborn B, Putzki N.

Swiss Med Wkly. 2011 May 3;141:w13192. doi: 10.4414/smw.2011.13192. eCollection 2011.

15.

Multiple sclerosis-associated fatigue during disease-modifying treatment with natalizumab, interferon-beta and glatiramer acetate.

Yildiz M, Tettenborn B, Putzki N.

Eur Neurol. 2011;65(4):231-2. doi: 10.1159/000324028. Epub 2011 Mar 31. No abstract available.

16.

Natalizumab and beyond.

Yildiz M, Tettenborn B, Putzki N.

Eur Neurol. 2010;64(4):236-40. doi: 10.1159/000317583. Epub 2010 Sep 4. No abstract available.

17.

Natalizumab treatment in paediatric multiple sclerosis: a case of induction, de-escalation and escalation.

Putzki N, Stich O, Gartzen K, Kastrup O, Tettenborn B, Rauer S.

Eur J Neurol. 2010 Nov;17(11):e105. doi: 10.1111/j.1468-1331.2010.03178.x. Epub 2010 Aug 16. No abstract available.

PMID:
20722710
18.

Peripheral nervous system involvement in multiple sclerosis.

Gartzen K, Katzarava Z, Diener HC, Putzki N.

Eur J Neurol. 2011 May;18(5):789-91. doi: 10.1111/j.1468-1331.2010.03149.x.

PMID:
20629712
19.

Headache in multiple sclerosis.

Putzki N, Katsarava Z.

Curr Pain Headache Rep. 2010 Aug;14(4):316-20. doi: 10.1007/s11916-010-0126-6. Review.

PMID:
20514531
20.

Effects of natalizumab on circulating B cells, T regulatory cells and natural killer cells.

Putzki N, Baranwal MK, Tettenborn B, Limmroth V, Kreuzfelder E.

Eur Neurol. 2010;63(5):311-7. doi: 10.1159/000302687. Epub 2010 May 5.

PMID:
20453514
21.

Corpus callosum index and long-term disability in multiple sclerosis patients.

Yaldizli O, Atefy R, Gass A, Sturm D, Glassl S, Tettenborn B, Putzki N.

J Neurol. 2010 Aug;257(8):1256-64. doi: 10.1007/s00415-010-5503-x. Epub 2010 Mar 3.

PMID:
20198382
22.

Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: results from a multicenter study in Switzerland.

Putzki N, Yaldizli O, Bühler R, Schwegler G, Curtius D, Tettenborn B.

Eur Neurol. 2010;63(2):101-6. doi: 10.1159/000276400. Epub 2010 Jan 16.

PMID:
20090344
23.

Fatigue is not associated with impaired function of regulatory T cells in untreated patients with multiple sclerosis.

Yaldizli O, Kumar M, Vago S, Kreuzfelder E, Limmroth V, Putzki N.

Eur Neurol. 2009;62(6):321-6. doi: 10.1159/000236375. Epub 2009 Sep 10.

PMID:
19752558
24.

Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.

Putzki N, Yaldizli O, Mäurer M, Cursiefen S, Kuckert S, Klawe C, Maschke M, Tettenborn B, Limmroth V.

Eur J Neurol. 2010 Jan;17(1):31-7. doi: 10.1111/j.1468-1331.2009.02728.x. Epub 2009 Jul 9.

PMID:
19614963
25.

Multiple sclerosis associated fatigue during natalizumab treatment.

Putzki N, Yaldizli O, Tettenborn B, Diener HC.

J Neurol Sci. 2009 Oct 15;285(1-2):109-13. doi: 10.1016/j.jns.2009.06.004. Epub 2009 Jun 26.

PMID:
19560168
26.

Quality of life in 1000 patients with early relapsing-remitting multiple sclerosis.

Putzki N, Fischer J, Gottwald K, Reifschneider G, Ries S, Siever A, Hoffmann F, Käfferlein W, Kausch U, Liedtke M, Kirchmeier J, Gmünd S, Richter A, Schicklmaier P, Niemczyk G, Wernsdörfer C, Hartung HP; "Mensch im Mittelpunkt" Study Group.

Eur J Neurol. 2009 Jun;16(6):713-20.

PMID:
19475754
27.

[Natalizumab and atypical naevi: Comments on the pharmacovigilance note by J.-L. Schmutz et al].

Yaldizli O, Baumberger P, Putzki N.

Ann Dermatol Venereol. 2009 May;136(5):450-1. doi: 10.1016/j.annder.2009.03.018. Epub 2009 Apr 21. French. No abstract available.

PMID:
19442806
28.

Natalizumab in the treatment of multiple sclerosis.

Yaldizli O, Putzki N.

Ther Adv Neurol Disord. 2009 Mar;2(2):115-28. doi: 10.1177/1756285608101861.

29.

Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis.

Putzki N, Kollia K, Woods S, Igwe E, Diener HC, Limmroth V.

Eur J Neurol. 2009 Mar;16(3):424-6. doi: 10.1111/j.1468-1331.2008.02519.x.

PMID:
19187261
30.

First clinical study on ultra-high-field MR imaging in patients with multiple sclerosis: comparison of 1.5T and 7T.

Kollia K, Maderwald S, Putzki N, Schlamann M, Theysohn JM, Kraff O, Ladd ME, Forsting M, Wanke I.

AJNR Am J Neuroradiol. 2009 Apr;30(4):699-702. doi: 10.3174/ajnr.A1434. Epub 2009 Jan 15.

31.

Prevalence of migraine, tension-type headache and trigeminal neuralgia in multiple sclerosis.

Putzki N, Pfriem A, Limmroth V, Yaldizli O, Tettenborn B, Diener HC, Katsarava Z.

Eur J Neurol. 2009 Feb;16(2):262-7. doi: 10.1111/j.1468-1331.2008.02406.x. Epub 2008 Dec 9.

PMID:
19138330
32.

Mitoxantrone does not restore the impaired suppressive function of natural regulatory T cells in patients suffering from multiple sclerosis. A longitudinal ex vivo and in vitro study.

Putzki N, Kumar M, Kreuzfelder E, Grosse-Wilde H, Diener HC, Limmroth V.

Eur Neurol. 2009;61(1):27-32. doi: 10.1159/000165346. Epub 2008 Oct 24.

PMID:
18948697
33.

Increased basal-ganglia activation performing a non-dystonia-related task in focal dystonia.

Obermann M, Yaldizli O, de Greiff A, Konczak J, Lachenmayer ML, Tumczak F, Buhl AR, Putzki N, Vollmer-Haase J, Gizewski ER, Diener HC, Maschke M.

Eur J Neurol. 2008 Aug;15(8):831-8. doi: 10.1111/j.1468-1331.2008.02196.x.

PMID:
18557921
34.

Habituation of the auditory startle response in cervical dystonia and Parkinson's disease.

Putzki N, Graf K, Stude P, Diener HC, Maschke M.

Eur Neurol. 2008;59(3-4):172-8. doi: 10.1159/000114038. Epub 2008 Jan 29.

PMID:
18230875
35.

Prevalence and severity of multiple-sclerosis-associated fatigue in treated and untreated patients.

Putzki N, Katsarava Z, Vago S, Diener HC, Limmroth V.

Eur Neurol. 2008;59(3-4):136-42. Epub 2007 Nov 30.

PMID:
18057900
36.

Relapsing neuromyelitis optica responsive to glatiramer acetate treatment.

Gartzen K, Limmroth V, Putzki N.

Eur J Neurol. 2007 Jun;14(6):e12-3. No abstract available.

PMID:
17539924
37.

Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosis.

Limmroth V, Malessa R, Zettl UK, Koehler J, Japp G, Haller P, Elias W, Obhof W, Viehöver A, Meier U, Brosig A, Hasford J, Putzki N, Kalski G, Wernsdörfer C; QUASIMS Study Group.

J Neurol. 2007 Jan;254(1):67-77. Epub 2007 Feb 1.

PMID:
17273808
38.

CD4+CD25+FoxP3+ T lymphocytes fail to suppress myelin basic protein-induced proliferation in patients with multiple sclerosis.

Kumar M, Putzki N, Limmroth V, Remus R, Lindemann M, Knop D, Mueller N, Hardt C, Kreuzfelder E, Grosse-Wilde H.

J Neuroimmunol. 2006 Nov;180(1-2):178-84. Epub 2006 Sep 29.

PMID:
17011048
39.

Secondary myelodysplastic syndrome following long-term treatment with azathioprine in patients with multiple sclerosis.

Putzki N, Knipp S, Ramczykowski T, Vago S, Germing U, Diener HC, Limmroth V.

Mult Scler. 2006 Jun;12(3):363-6.

PMID:
16764353
40.

Kinesthesia is impaired in focal dystonia.

Putzki N, Stude P, Konczak J, Graf K, Diener HC, Maschke M.

Mov Disord. 2006 Jun;21(6):754-60.

PMID:
16482525
41.

Trigeminal autonomic cephalalgias: a case of post-traumatic SUNCT syndrome?

Putzki N, Nirkko A, Diener HC.

Cephalalgia. 2005 May;25(5):395-7. No abstract available.

PMID:
15839855
42.

High-dose, frequently administered interferon beta.

Limmroth V, Putzki N.

J Neurol Sci. 2005 Apr 15;231(1-2):95-6; author reply 97-9. Epub 2005 Jan 27. No abstract available.

PMID:
15792828
43.

Nociceptive-specific blink reflex and glyceryl trinitrate infusion in healthy volunteers.

Kowacs F, Giffin NJ, Putzki N, Goadsby PJ, Kaube H.

Eur J Neurol. 2003 May;10(3):295-9.

PMID:
12752404
44.

Effect of functional NMDA-antagonist flupirtine on automatic postural responses in Parkinson's disease.

Putzki N, Maschke M, Drepper J, Diener HC, Timmann D.

J Neurol. 2002 Jul;249(7):824-8.

PMID:
12140664

Supplemental Content

Loading ...
Support Center